Developments relevant to general practice and primary care — service changes, family-history guidance, and what's shifting in how genetics meets the front line.
41 stories · Last updated
Zanvastro has received FDA approval for Alexander disease, a devastating ultra-rare neurological disorder, marking the culmination of more than 30 years of scientific work on this leukodystrophy.
A newly characterised protective variant appears to block harmful protein accumulation in the brains of high-genetic-risk individuals who remain cognitively sharp into their eighties.
Researchers at the Mayo Clinic have shown that metabolic dysfunction-associated steatotic liver disease is not a single condition but a cluster of five molecularly distinct entities, each with differing complication profiles.
A first-person account published in Stat News describes how one family's search for a diagnosis for a hereditary neurological condition — referred to only as 'it' for decades — ultimately led to identification of a named rare disease.
Stanford geneticist Euan Ashley argues that Claude completing a whole-genome analysis in under an hour for roughly $5 has outpaced the ethical and regulatory frameworks governing such outputs.
STAT News reports that exon-skipping therapies approved for Duchenne muscular dystrophy — including candidates from Novartis and Dyne — remain inaccessible to most patients who could benefit, testing the FDA's rare-disease drug framework.
An FDA advisory committee has concluded that the benefits of Galleri, a circulating-tumour-DNA screening test covering multiple cancer types, outweigh its risks.
A Cancer Research UK feature examines how the CanRisk programme uses germline variant data, polygenic scores, and questionnaire-based risk factors to stratify breast cancer risk beyond BRCA1 and BRCA2.
A UK-first pilot across specialist centres in England aims to cut the time from biopsy to definitive brain tumour diagnosis from weeks to days using genomic profiling.
Researchers have shown that the APOE4 genetic risk variant for Alzheimer's disease actively disrupts cerebrovascular function and protein-clearance systems, and some of these effects could be reversed experimentally.
A STAT News opinion piece contends that Grail's Galleri test does not meet the evidentiary bar for approval, warning that detecting more cancers does not automatically translate to lives saved.
A 54-year-old mystery in transfusion medicine is resolved as researchers pinpoint the gene responsible for the AnWj antigen, opening a route to safer matching for rare AnWj-negative patients.
The FDA has approved Scholar Rock's Isembyld for spinal muscular atrophy, the first therapy to address the muscle-wasting component of the disease when combined with an SMN2-targeting agent.
NHS England has directed every trust to suspend staff and revoke system access immediately upon suspicion of improper access to patient medical records, formalising a zero-tolerance approach to data snooping.
A medical student opinion piece in Stat News argues that the alcohol-flushing response common in people of East Asian ancestry reflects ALDH2 variant biology and that its health implications are under-communicated in clinical settings.
A new commentary from the PHG Foundation sets out why fragmented deployment infrastructure is a key barrier to realising the potential of disease risk prediction tools in general practice.
A large observational and genetic analysis of more than 270,000 individuals associates higher circulating tyrosine with reduced life expectancy in men, with no equivalent signal detected in women.
A new commentary from the PHG Foundation at the University of Cambridge argues that deploying disease risk prediction models in primary care requires overcoming organisational and workflow challenges that go well beyond model accuracy.
NHS England begins distributing home HPV self-sampling kits to women aged 30–65 who have not responded to cervical screening invitations, aiming to increase uptake.
The US Food and Drug Administration has licensed mFluSIva, Moderna's messenger RNA flu shot, marking the first regulatory approval of mRNA technology for influenza.
An FDA advisory committee is scheduled to weigh the evidence for Grail's Galleri blood-based multi-cancer detection test, a decision with broad implications for the emerging field of cell-free DNA screening.
A new policy analysis from the PHG Foundation considers what an updated, polygenic-score-integrated BOADICEA model means for how familial breast-cancer risk should be assessed at a population level.
A major genome-wide study has expanded the known genetic architecture of hyperemesis gravidarum to ten risk genes, several of which implicate appetite and nausea regulation pathways.
A new briefing from the PHG Foundation at the University of Cambridge outlines recommendations for EU and national governments seeking to embed genomics-informed prevention into health systems.
Cancer Research UK's policy team examines whether commitments in the National Cancer Plan are sufficient to meet the ambition of expanding clinical trial access in the UK.
Columbia University researchers report that a specific genetic variant may accelerate heart valve damage in people with degenerative mitral regurgitation who also take SSRI antidepressants.
Cancer Research UK reports that new data provide the strongest evidence to date that the UK HPV vaccination programme is reducing not only cervical cancer incidence but cervical cancer mortality.
Michelle Sie Whitten of the Global Down Syndrome Foundation writes in STAT News that women receiving a prenatal Down syndrome diagnosis are routinely given outdated or incomplete information about life expectancy and quality of life.
A cross-cohort analysis of nearly 20,000 individuals from four British birth cohort studies shows that polygenic risk for high body mass index became a stronger predictor of observed BMI in cohorts born later into the obesity epidemic.
The world's first randomised trial of a multi-cancer early detection blood test did not meet its primary endpoint, though commentators argue the results carry important signals for the field of early-detection genomics.
A preprint from Cold Spring Harbor Laboratory describes a 'dish-to-biobank' framework that connects controlled glucolipotoxicity stress in stem-cell-derived beta cells to population-scale type 2 diabetes genetics via the plasma proteome.
Phase 3 results for Revolution Medicines' daraxonrasib show a 60% reduction in risk of death compared with standard chemotherapy, marking the first practice-changing advance for KRAS-mutant pancreatic cancer.
The UK National Screening Committee has endorsed a risk-stratified approach to prostate cancer screening, focusing on men who carry a BRCA2 pathogenic variant and have a relevant family history of cancer.
A study has identified heritable variants that appear to reduce responsiveness to GLP-1 receptor agonists in clinical trials, potentially explaining why a subset of patients fail to reach glycaemic targets.
New NHS England data show that mobile scanning units deployed at supermarkets, sports stadiums and high streets have detected 10,678 lung cancers, more than three-quarters at stages one or two.
A specialist First Opinion piece in STAT News draws three lessons from the world's first randomised trial of a multi-cancer early detection blood test, which did not meet its primary endpoint.
Cancer Research UK analysis shows melanoma incidence has reached its highest recorded level in the UK, raising questions about prevention, surveillance, and the role of genetic risk factors.
Nusinersen and risdiplam will be routinely available on the NHS in England following an evidence-collection access scheme, giving families with spinal muscular atrophy long-term certainty.
A new systematic review published in 2026 concludes that prostate-specific antigen blood testing likely reduces the risk of death from prostate cancer, though over-diagnosis and over-treatment remain concerns.
A PHG Foundation analysis highlights how genetic variants affecting red blood cell biology can cause HbA1c to misclassify diabetes risk, with disproportionate impact across ancestry groups.
A paper in Nature Medicine reports that Australia has passed legislation preventing life insurers from using genetic test results to discriminate against applicants — a significant regulatory development with implications for genetic testing uptake.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List